Heartflow (NASDAQ:HTFL) Price Target Raised to $70.00

Heartflow (NASDAQ:HTFL) had its price target hoisted by equities researchers at Wells Fargo & Company from $39.00 to $70.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 40.05% from the company’s current price.

Several other brokerages have also recently issued reports on HTFL. Morgan Stanley lifted their price objective on Heartflow from $35.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 14th. Stifel Nicolaus upped their target price on shares of Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Canaccord Genuity Group lifted their price target on shares of Heartflow from $56.00 to $69.00 and gave the stock a “buy” rating in a research note on Friday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Heartflow has an average rating of “Moderate Buy” and a consensus price target of $60.12.

Heartflow Trading Down 16.6%

NASDAQ:HTFL traded down $9.94 during midday trading on Friday, reaching $49.98. The company had a trading volume of 1,650,276 shares, compared to its average volume of 1,609,452. The firm has a market capitalization of $4.35 billion, a price-to-earnings ratio of -27.35 and a beta of 2.50. The stock’s fifty day simple moving average is $51.93 and its 200-day simple moving average is $35.14. Heartflow has a 12-month low of $20.13 and a 12-month high of $60.65.

Heartflow (NASDAQ:HTFL) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The company had revenue of $72.86 million for the quarter. During the same quarter last year, the company earned ($0.27) EPS. As a group, sell-side analysts expect that Heartflow will post -0.75 EPS for the current year.

Insider Buying and Selling

In other Heartflow news, CEO John Farquhar sold 38,900 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $55.74, for a total value of $2,168,286.00. Following the transaction, the chief executive officer directly owned 251,983 shares in the company, valued at $14,045,532.42. This represents a 13.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Campbell Rogers sold 23,933 shares of the firm’s stock in a transaction that occurred on Thursday, October 22nd. The stock was sold at an average price of $55.01, for a total transaction of $1,316,554.33. Following the sale, the insider directly owned 73,453 shares in the company, valued at approximately $4,040,649.53. The trade was a 24.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 332,403 shares of company stock worth $16,602,786 over the last 90 days. 7.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. XXEC Inc. purchased a new position in shares of Heartflow in the 2nd quarter valued at $2,524,764,000. BlackRock Inc. acquired a new stake in Heartflow during the 2nd quarter worth $152,502,000. Bamco Inc. NY acquired a new stake in Heartflow during the 2nd quarter worth $94,625,000. Jupiter Topco LLC acquired a new stake in Heartflow during the 2nd quarter worth $70,983,000. Finally, Janus Henderson Group PLC lifted its position in Heartflow by 152.0% in the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after acquiring an additional 1,315,416 shares during the last quarter.

More Heartflow News

Investors following HTFL have been watching these news items:

• Positive Sentiment: Q3 results beat expectations. HeartFlow reported revenue of $72.9 million, above the $65.2 million FactSet estimate, and a loss of $0.03 per share versus the consensus estimate of a $0.18 loss. The per-share loss also narrowed from $0.27 a year earlier. Zacks Q3 results article
• Positive Sentiment: 2026 revenue outlook rose above expectations. The company guided to $262 million–$264 million in revenue, versus analyst estimates around $248.5 million, signaling stronger expected growth. HeartFlow Q3 results and guidance
• Positive Sentiment: Analysts raised targets and maintained bullish ratings. Stifel lifted its target to $70 with a buy rating; Canaccord raised its target to $69 with a buy rating; and Baird increased its target to $68 with an outperform rating. These revisions reflect greater potential upside in analysts’ views.

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.